Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Peripheral Arterial Disease
Interventions
BIOLOGICAL

Ixmyelocel-T

IM injection

BIOLOGICAL

Placebo

IM Injection

Trial Locations (20)

15213

University of Pittsburgh Medical Center, Pittsburgh

27514

University of North Carolina Hospitals, Chapel Hill

32608

Malcolm Randall Veterans Administration Medical Center, part of the North Florida/South Georgia Veterans Health System, Gainesville

33136

University of Miami/Miller School of Medicine, Miami

35211

Cardiology, P.C., Birmingham

43606

Jobst Vascular Center, Toledo

46260

The Care Group, LLC, Indianapolis

48105

VA Ann Arbor Healthcare System, Ann Arbor

48106

St. Joseph Mercy Hospital, Ann Arbor

48507

Michigan Vascular Research Center, Flint

55407

Minneapolis Heart Institute Foundation, Minneapolis

60153

Loyola University Stritch School of Medicine, Maywood

62702

Southern Illinois University School of Medicine, Springfield

73104

Oklahoma University, Oklahoma City

76508

Scott and White Hospital, Temple

78205

Peripheral Vascular Associates, San Antonio

85006

Arizona Heart Institute, Phoenix

94143

University of California, San Francisco, San Francisco

03756

Dartmouth-Hitchcock Memorial Center, Lebanon

37232-2735

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Vericel Corporation

INDUSTRY

NCT00468000 - Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia | Biotech Hunter | Biotech Hunter